Holen Sie sich die Stockscreener-App
228.93
0.57%
-1.37
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ABBV?
Forum
Prognose
Dividendenhistorie
Schlusskurs vom Vortag:
$230.30
Offen:
$228.07
24-Stunden-Volumen:
2.21M
Relative Volume:
0.42
Marktkapitalisierung:
$404.47B
Einnahmen:
$58.33B
Nettoeinkommen (Verlust:
$3.73B
KGV:
108.95
EPS:
2.1013
Netto-Cashflow:
$18.24B
1W Leistung:
-1.65%
1M Leistung:
+4.87%
6M Leistung:
+27.85%
1J Leistung:
+17.04%
1-Tages-Spanne:
$227.51
$230.65
1-Wochen-Bereich:
$227.51
$234.68
52-Wochen-Spanne:
$163.81
$244.81
Abbvie Inc Stock (ABBV) Company Profile
Firmenname
Abbvie Inc
Sektor
Telefon
(847) 932-7900
Adresse
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Vergleichen Sie ABBV mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
228.96 | 406.84B | 58.33B | 3.73B | 18.24B | 2.1013 |
|
LLY
Lilly Eli Co
|
814.04 | 747.19B | 53.26B | 13.80B | -50.20M | 15.08 |
|
JNJ
Johnson Johnson
|
188.04 | 459.32B | 90.62B | 22.66B | 18.18B | 9.35 |
|
NVS
Novartis Ag Adr
|
129.88 | 249.96B | 53.40B | 13.68B | 16.89B | 6.8864 |
|
MRK
Merck Co Inc
|
84.82 | 214.78B | 63.43B | 16.42B | 14.72B | 6.4861 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-01 | Herabstufung | HSBC Securities | Buy → Hold |
| 2025-09-17 | Hochstufung | Berenberg | Hold → Buy |
| 2025-08-12 | Fortgesetzt | Piper Sandler | Overweight |
| 2025-08-07 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2025-05-14 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-12-05 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2024-11-22 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-11-04 | Hochstufung | Argus | Hold → Buy |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-06-05 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-05-17 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-01-29 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2023-12-18 | Herabstufung | HSBC Securities | Buy → Hold |
| 2023-12-11 | Hochstufung | Goldman | Neutral → Buy |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-10-30 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2023-10-20 | Fortgesetzt | UBS | Neutral |
| 2023-09-29 | Eingeleitet | Raymond James | Outperform |
| 2023-07-25 | Eingeleitet | William Blair | Mkt Perform |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-04-05 | Herabstufung | Argus | Buy → Hold |
| 2023-03-01 | Eingeleitet | Guggenheim | Buy |
| 2023-02-22 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2023-02-10 | Hochstufung | SVB Securities | Underperform → Market Perform |
| 2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
| 2022-11-08 | Herabstufung | Societe Generale | Buy → Hold |
| 2022-08-01 | Herabstufung | Atlantic Equities | Overweight → Neutral |
| 2022-05-23 | Eingeleitet | SVB Leerink | Underperform |
| 2022-05-06 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-02-28 | Herabstufung | UBS | Buy → Neutral |
| 2022-02-03 | Bestätigt | BMO Capital Markets | Outperform |
| 2022-02-03 | Bestätigt | Barclays | Equal Weight |
| 2022-02-03 | Bestätigt | BofA Securities | Neutral |
| 2022-02-03 | Bestätigt | Goldman | Neutral |
| 2022-01-13 | Eingeleitet | Redburn | Buy |
| 2022-01-12 | Bestätigt | BMO Capital Markets | Outperform |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Overweight |
| 2021-11-23 | Hochstufung | Societe Generale | Hold → Buy |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2020-11-10 | Fortgesetzt | Bernstein | Outperform |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-06-23 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2020-06-09 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2020-06-02 | Hochstufung | Argus | Hold → Buy |
| 2020-05-18 | Fortgesetzt | BofA/Merrill | Neutral |
| 2020-05-12 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-05-11 | Fortgesetzt | Morgan Stanley | Overweight |
| 2020-04-20 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-03-23 | Herabstufung | Societe Generale | Buy → Hold |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-02-06 | Eingeleitet | Mizuho | Buy |
| 2020-01-07 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2019-12-26 | Bestätigt | Cowen | Outperform |
| 2019-09-26 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-08-20 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2019-06-27 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2019-06-26 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-05-28 | Eingeleitet | Goldman | Neutral |
| 2019-04-29 | Hochstufung | BMO Capital Markets | Underperform → Market Perform |
Alle ansehen
Abbvie Inc Aktie (ABBV) Neueste Nachrichten
Amazon, AbbVie, Datadog And A Financial Stock: CNBC's 'Final Trades' - Benzinga
Does AbbVie's Latest AI Partnership Signal More Room for Its 2025 Rally? - Yahoo Finance
The Best Dividend ETF to Invest $500 in Right Now - The Motley Fool
Abbvie gets USFDA approval for updated indication statement for Rinvoq for Inflammatory Bowel Disease - Medical Dialogues
Pharma companies announce direct-to-consumer sales and price cuts in US - Reuters
FDA Expands AbbVie's Rinvoq (ABBV) Indication for Colitis and Cr - GuruFocus
FDA Expands AbbVie's (ABBV) RINVOQ Approval for Ulcerative Colit - GuruFocus
AbbVie Stock Rises After FDA Approves Changed Recommendations For Use Of Popular Rinvoq Drug - Stocktwits
FDA approves updated indication for AbbVie’s RINVOQ in IBD treatment - Investing.com
Use after 1 approved systemic therapy — AbbVie gets FDA approval to update RINVOQ IBD label allowing pre‑TNF use - Stock Titan
2 Dividend Stocks to Double Up on Right Now - The Globe and Mail
Abbvie to Present New Data At Esmo 2025 Reinforcing Leadership in Advancing Targeted Therapies for Solid Tumors - MarketScreener
AbbVie to Present New Data at ESMO 2025 Reinforcing Leadership in Advancing Targeted Therapies for Solid Tumors - Investing News Network
AbbVie (ABBV) to Present New Antibody-Drug Conjugate Data at ESM - GuruFocus
Atria Wealth Solutions Inc. Reduces Position in AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. $ABBV Shares Sold by Envestnet Portfolio Solutions Inc. - MarketBeat
Concord Asset Management LLC VA Purchases 1,691 Shares of AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. $ABBV Shares Sold by Vest Financial LLC - MarketBeat
Griffin Asset Management Inc. Lowers Stake in AbbVie Inc. $ABBV - MarketBeat
M.E. Allison & CO. Inc. Has $466,000 Stake in AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. $ABBV Shares Acquired by MOKAN Wealth Management Inc. - MarketBeat
AbbVie Inc. $ABBV is Welch Group LLC's 9th Largest Position - MarketBeat
Almanack Investment Partners LLC. Boosts Stock Holdings in AbbVie Inc. $ABBV - MarketBeat
Criteria Caixa S.A.U. Sells 47,822 Shares of AbbVie Inc. $ABBV - MarketBeat
Cwm LLC Has $60.03 Million Holdings in AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. $ABBV is Advocate Group LLC's 4th Largest Position - MarketBeat
Vanguard Personalized Indexing Management LLC Acquires 37,680 Shares of AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. $ABBV Shares Bought by OFI Invest Asset Management - MarketBeat
Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. Buys Shares of 23,920 AbbVie Inc. $ABBV - MarketBeat
Sather Financial Group Inc Purchases New Position in AbbVie Inc. $ABBV - MarketBeat
2,500 Shares in AbbVie Inc. $ABBV Bought by Summa Corp. - MarketBeat
Johnson Investment Counsel Inc. Lowers Holdings in AbbVie Inc. $ABBV - MarketBeat
Why Analysts See AbbVie’s Story Shifting After Strategic Wins and Growth Upgrades - Yahoo Finance
AbbVie Inc. $ABBV Holdings Lowered by Natural Investments LLC - MarketBeat
Fifth Third Wealth Advisors LLC Sells 4,542 Shares of AbbVie Inc. $ABBV - MarketBeat
One Degree Advisors Inc Buys New Position in AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. $ABBV Shares Acquired by Conning Inc. - MarketBeat
Drucker Wealth 3.0 LLC Purchases 2,817 Shares of AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. $ABBV Shares Acquired by Eastern Bank - MarketBeat
Forefront Analytics LLC Invests $1.28 Million in AbbVie Inc. $ABBV - MarketBeat
Lmcg Investments LLC Decreases Stock Position in AbbVie Inc. $ABBV - MarketBeat
Strong Tower Advisory Services Raises Stock Position in AbbVie Inc. $ABBV - MarketBeat
AbbVie (NYSE:ABBV) Lowered to Hold Rating by Wall Street Zen - MarketBeat
AbbVie And Amgen's Blueprint To Digitalize Biomanufacturing - Bioprocess Online
Goldman Sachs Adjusts AbbVie Price Target to $218 From $217, Maintains Neutral Rating - MarketScreener
Why AbbVie Inc. is moving todayJuly 2025 Price Swings & Consistent Growth Equity Picks - newser.com
Piper Sandler raises Abbvie stock price target to $284 on strong portfolio - Investing.com Canada
Piper Sandler Raises Price Target for AbbVie (ABBV) to $284, Mai - GuruFocus
Is Trending Stock AbbVie Inc. (ABBV) a Buy Now? - Yahoo Finance
Blue Trust Inc. Trims Position in AbbVie Inc. $ABBV - MarketBeat
Cyndeo Wealth Partners LLC Grows Stake in AbbVie Inc. $ABBV - MarketBeat
Finanzdaten der Abbvie Inc-Aktie (ABBV)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.53%
0.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):